Elaprase

Selected form

Idursulfase

Method of action: Other Alimentary Tract And Metabolism Products, Replenishment Of Deficiency Of Idroonate-2-Sulfatase

Treatment option: Hunter Syndrome

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elaprase

Property	Description
Active ingredient	Idursulfase
Form	Sterile Solution for Injection
Pharmacological class	Enzyme Replacement Therapy (ERT)
General purpose	Addresses enzymatic deficiency in Hunter syndrome (MPS II)
Origin	Biotechnologically-derived (Recombinant Human Enzyme)

What Type of Medicine is Elaprase (Idursulfase)?

Elaprase is a prescription-only medicine containing the active ingredient Idursulfase, a highly purified form of human iduronate-2-sulfatase. It is classified as an Enzyme Replacement Therapy (ERT), belonging to the pharmacological class of Hydrolytic Lysosomal Glycosaminoglycan-specific Enzymes. Idursulfase represents a distinctive therapeutic strategy as a biotechnologically-derived product, being a recombinant human enzyme manufactured using cell lines to replicate the deficient natural protein. This method of production is recognized for ensuring the high fidelity and function necessary for the enzyme to be effective within the body.

Composition and Form: What is Elaprase Made Of?

The medicine is supplied as a single-component product formulated as a sterile solution for injection. The composition consists of the active enzyme, Idursulfase, contained within an aqueous base/vehicle stabilized with excipients appropriate for its delivery. Due to its complex protein structure and the need for systemic distribution, Elaprase is strictly administered via Intravenous Infusion, which is the defined route of administration. This delivery method is a critical factor ensuring the active enzyme bypasses the digestive system and is available in the bloodstream to reach target tissues.

What is the General Therapeutic Purpose of Elaprase?

The general purpose of Elaprase is to address the underlying enzymatic defect in Hunter syndrome, scientifically known as Mucopolysaccharidosis II (MPS II). As an ERT, its function is to provide the patient's cells with the missing iduronate-2-sulfatase enzyme. This replacement is designed to facilitate the degradation of glycosaminoglycans (GAGs), complex sugar molecules that otherwise accumulate abnormally within the lysosomes. This therapeutic intervention aims to manage the progressive, systemic impact of the storage disorder by providing the essential biological tool needed for cellular function.

Regulatory References

What side effects are possible with Elaprase?

Possible Side Effects and Safety Information

The safety profile for Elaprase (Idursulfase) is primarily characterized by the risk of Infusion-Related Reactions (IRRs), which are documented as the most frequently reported adverse events. The official safety information organizes potential effects into categories based on their frequency of occurrence, as established in regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Frequency-Classified Adverse Reactions

The following are examples of adverse reactions listed by their regulatory frequency classification:

Very Common (ge 1 in 10 patients): These include systemic effects such as headache, pyrexia (fever), chills, and gastrointestinal effects like vomiting and abdominal pain. Skin reactions such as rash and urticaria are also classified here.
Common (ge 1 in 100 to < 1 in 10 patients): These reactions include hypotension (low blood pressure), hypertension (high blood pressure), tachycardia (increased heart rate), and peripheral edema.
Uncommon (ge 1 in 1,000 to < 1 in 100 patients): The most serious events, such as anaphylactic reaction, are formally classified within this category.

Serious Adverse Reactions and Safety Patterns

The most significant risks documented in regulatory labels are anaphylaxis and severe Infusion-Related Reactions (IRRs), which may manifest as respiratory distress or severe hypotension. A history of life-threatening anaphylactic reaction to Idursulfase is established as a formal contraindication in the regulatory safety profile. Furthermore, adverse reactions, particularly IRRs, are explicitly documented as being more common during and following the initial 12 weeks of treatment.

Population-specific safety considerations note that patients with pre-existing respiratory compromise or severe cardiac function impairment may be at increased risk of severe reactions during administration.

Overdose and Emergency Response

The official regulatory documents for Elaprase (Idursulfase) state there is no clinical experience documenting a classical dose-related overdosage in human patients. Consequently, the regulatory profile focuses exclusively on the potential for severe, life-threatening hypersensitivity reactions, including anaphylaxis, which are the events that necessitate immediate emergency action.

Official Manifestations and Outcomes Severe acute reactions may involve multiple physiological systems. Documented manifestations include respiratory distress, hypoxia, and angioedema of the throat or tongue. Cardiovascular signs such as hypotension and neurological signs such as seizure and loss of consciousness have been reported. The most serious outcomes documented include the potential for cardiorespiratory arrest and respiratory failure. Specific patient populations, including those with compromised respiratory or cardiac function, are noted to be at risk for serious exacerbations during these reactions.

Mandated Emergency Action Regulatory authorities mandate that if any signs of a severe reaction occur, the infusion must be immediately discontinued. Patients and caregivers are explicitly instructed to seek immediate medical care. Management involves initiating appropriate supportive treatment, which includes the availability and use of medications such as epinephrine, antihistamines, and corticosteroids. Patients experiencing severe or refractory reactions may require prolonged clinical monitoring.

Therapeutic Uses of Elaprase

What Elaprase Treats: Main Uses and Benefits

Elaprase (Idursulfase) is an enzyme replacement therapy (ERT) used for the long-term management of Hunter syndrome (Mucopolysaccharidosis II, MPS II). The therapy is relevant in contexts involving heightened systemic burden, addressing the physical manifestations that create noticeable physiological strain. The medication is applied in conditions characterized by periods of heightened symptoms, including difficulty breathing and difficulty walking, which are common manifestations. The medication is applied in clinical settings that involve acute or unstable symptom patterns. The treatment supports patients with these specific needs.

Quick Fact: Focus on Physical Mobility and Organ Stress

Indications include managing musculoskeletal limitations, organ enlargement, and pulmonary decline. Elaprase helps address symptom clusters that may become intense or disruptive in three primary domains: it supports functional stability related to physical movement, helps ease the overall symptom burden associated with organ-specific functional stress, and contributes to easing challenging manifestations related to respiratory function.

Eligibility and Restrictions for Use

Who Can and Cannot Use Elaprase?

Regulatory authorities define eligibility for Elaprase (Idursulfase) based on age and clinical status. The medicine is approved for the treatment of Hunter syndrome in patients 16 months of age and older.

Absolute Exclusion and Age Limits

Use is strictly contraindicated for individuals with a history of severe or life-threatening hypersensitivity (anaphylaxis) to the drug or any of its ingredients, particularly when the reaction is not controllable.

Use is not established in pediatric patients less than 16 months of age or in adults over 65 years of age, as clinical experience is lacking in these specific groups.

Conditional Use and Restrictions

Patients with compromised respiratory function, severe underlying airway disease, or susceptibility to fluid overload require special care and close monitoring during the infusion process. There is also no clinical experience for patients with renal or hepatic insufficiency.

Use is not recommended during pregnancy as a precautionary measure due to limited data, and caution is advised during lactation.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Elaprase

Interaction scope

Medicinal product categories with documented interactions include sedative medicinal products, such as antihistamines, which may be used during the management of infusion-related reactions. No specific drug agents are explicitly listed in regulatory documents as altering the plasma concentration of Elaprase or being altered by it.

The mechanistic basis of this documented interaction is pharmacodynamic, stemming from the potential for additive effects that could compromise respiratory function. The official profile for Elaprase states that based on its cellular lysosomal metabolism, it is not a candidate for cytochrome P450 mediated interactions, eliminating this major pathway for drug-drug interactions.

Timing and Population Notes

A timing-based interaction rule requires mandatory physical separation: Elaprase must not be infused with other products in the infusion tubing. A population-specific interaction note highlights that the pharmacodynamic risk associated with sedative medicinal products is increased for patients with compromised respiratory function or acute respiratory disease, necessitating careful monitoring.

Interaction classifications (high-level)

Interaction severity classification is Cautionary Use Required for sedative agents. No formal drug-drug combinations are classified as contraindicated. Interaction-context constraints are procedural (no co-infusion) and relate to infusion reaction management.

Resulting interaction structure

Official documentation confirms that Elaprase has no anticipated interactions mediated by the CYP450 enzyme system. The key regulatory constraints define administration procedures, strictly prohibiting co-infusion with other products, and mandate the limitation or careful monitoring of sedative medicinal products when managing infusion reactions. This comprehensive structure strictly defines the procedural and pharmacodynamic cautions without relying on general safety warnings.

Mechanism of Action

How Elaprase Works: Mechanism of Action

Enzymatic Action in Lysosomal Catabolism

The drug's primary action is enzyme replacement. The active enzyme, idursulfase, is an exogenous enzyme that functions as a replacement protein for the deficient alpha-L-iduronidase. It acts through a catabolic mechanism by directly catalyzing the breakdown of accumulated glycosaminoglycans (GAGs). This action modifies the substrate composition within the cell's lysosomes, establishing the basis for subsequent alterations in tissue morphology.

Targeted Delivery to Intracellular Compartments

This domain explains the specialized transport mechanism. The enzyme utilizes mannose-6-phosphate (M6P) receptors on the cell surface for receptor-mediated endocytosis. This process is responsible for delivering the enzyme to the lysosomes where the GAGs are stored. This mechanism directs the enzyme to the required intracellular compartment, which supports the systemic distribution of the catabolic effect across various affected tissues.

Molecular Action Influencing Tissue Morphology

This addresses the mechanistic cascade from the molecular to the systemic level. The enzymatic breakdown of GAGs modifies the cellular and tissue effects resulting from substrate storage. This molecular action influences the overall morphology of the cells and tissues, including peripheral organs and connective tissues.

Dosage and Administration Information

How to Use Elaprase (Idursulfase)

Elaprase is administered strictly by intravenous (IV) infusion and is intended for long-term treatment. The instructions for its use are precisely defined to ensure proper delivery.

Dosage and Frequency

The recommended dose is 0.5 mg per kg of body weight, which must be accurately calculated before each infusion. Elaprase is given once weekly.

Administration Detail	Requirement
Route	Intravenous (IV) infusion only
Dosing	0.5 mg per kg of body weight
Frequency	Once every week (weekly)

Preparation and Administration Protocol

The medicine is supplied as a concentrate that requires careful dilution before administration. The calculated volume of the concentrate must be mixed gently (do not shake) into a 100 mL bag of 0.9% Sodium Chloride Injection, USP (saline). The solution should be allowed to reach room temperature before preparation.

Administration requires the use of a low-protein-binding infusion set equipped with a low-protein-binding 0.2 micrometer (mu m) in-line filter. The infusion must not be given with other products in the same IV line.

Infusion Procedure

Infusion is typically administered over a period of 3 hours, although this time may be gradually reduced to 1 hour in patients who tolerate the infusion well. The total infusion time should not exceed 8 hours. The infusion rate is carefully managed and may be slowed or temporarily stopped if reactions occur. Patients are required to be closely monitored during and immediately following the infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elaprase

Evidence for Use in Functional Mobility and Physical Status

Research exploring outcomes related to physical discomfort included the use of randomized, placebo-controlled trials (RCTs). These studies were used in research exploring how symptoms change over time. Research examined outcomes reflecting daily functioning and activity level, particularly the ability to walk or physical stamina. Researchers measured this outcome using the standardized 6-Minute Walk Test distance. Studies also monitored pulmonary function through standardized lung capacity measurements. The populations observed in these initial controlled studies included children, adolescents, and adults (ages 5 to 31 years).

Studies reported measurements of the walking distance achieved by patients during the study period. Findings described patterns observed in the studies related to changes monitored in pulmonary function outcomes, which were reported to vary across groups and timeframes. While the studies monitored these physiological outcomes, long-term effects are not fully established in this area, particularly for respiratory function.

Evidence for Use in Biochemical Activity and Organ Volume

Research explored studies that examined outcomes related to systemic or functional imbalance in Hunter syndrome. Studies monitored outcomes related to systemic or functional imbalance, such as the size of the liver and spleen, using imaging techniques. Biochemical outcomes were tracked by monitoring the levels of accumulated GAGs in the urine. These research scenarios were applied in studies focusing on organ enlargement.

Studies reported patterns observed in the changes in these biomarkers during the observation periods. Findings also described changes measured during the study period for the volume of the liver and spleen. The evidence provides insight into these patterns, but it is not yet clear whether there is an exact relationship between the magnitude of these changes and a patient's overall physical status.

Key Evidence Gaps and Areas of Research Uncertainty

The evidence highlights what is known, but also areas of research uncertainty. One key limitation is that the original pivotal trial had a modest sample size, which is common for studies on rare conditions. Furthermore, comparative evidence is lacking for many long-term clinical outcomes. For example, while studies monitored different outcomes for pulmonary function, the findings were mixed, and the overall pattern of stability or change in lung capacity long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Elaprase (FAQ)

Q: What is Elaprase used for?

Elaprase (Idursulfase) is an enzyme replacement therapy indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). It is used to treat some non-neurological symptoms of the condition.

Q: How is Elaprase administered?

Elaprase is administered by a healthcare professional as an intravenous infusion. It is typically given once weekly. The administration is performed in a clinic or healthcare setting.

Q: Are there important safety warnings for Elaprase?

Serious allergic reactions, known as anaphylaxis, have been reported in patients during or after treatment with Elaprase. The treatment should be administered in a setting where appropriate medical support for managing these reactions is immediately available. Infusion-related reactions are also common.

Q: Can Elaprase cure Hunter syndrome?

Elaprase is not a cure for Hunter syndrome. It is a long-term enzyme replacement therapy designed to manage some symptoms of the condition by replacing the missing enzyme, iduronate-2-sulfatase.

Q: What are the common side effects of Elaprase?

Common side effects observed during clinical trials included headache, fever, rash, itching, and other infusion-related reactions. Patients should discuss all potential side effects and safety information with a healthcare provider.

How should Elaprase be stored and disposed of?

How to Store and Dispose of Elaprase

Elaprase (idursulfase) must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage and Handling Conditions

Condition	Requirement (Unopened Vials)	Requirement (Diluted Solution)
Temperature	Store refrigerated at 2 C to 8 C (36 F to 46 F).	Use immediately; if delayed, store refrigerated at 2 C to 8 C for up to 24 hours.
Protection	Store in the original carton to protect from light.	Must not be stored at room temperature.
Prohibitions	Do not freeze. Do not shake.	Do not freeze.
Safety	Keep the medicine out of the reach of children.

Elaprase vials are for single-use only. Do not use the product past the expiration date on the label.

Disposal Instructions

Any unused product, remaining material, or waste must be discarded and disposed of in accordance with local requirements for pharmaceutical waste. The product must not be disposed of in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.